(Q36836587)

16 August 2017

1 reference

title

The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications (English)

1 reference

16 August 2017

1 reference

Steven G Chrysant

1

1 reference

16 August 2017

language of work or name

1 reference

1 June 2007

1 reference

Journal of Clinical Hypertension

16 August 2017

published in

1 reference

16 August 2017

volume

9

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

454-459

1 reference

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Does angiotensin-II protect against strokes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.06602.X

10.1111/J.1524-6175.2007.06602.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference